BRASIL'S FAILURE TO PROVIDE ADEQUATE PATENT PROTECTION FOR PHARMACEUTICALS WAS UNACCEPTABLE, STRESSING THE VITAL IMPORTANCE OF PROTECTING INVENTIONS AND DISCOVERIES MADE IN BILATERAL TRADE AGREEMENTS.

The PLM speakers stressed that the lack of appropriate patent protection results in a failure to support Brazil's current pharmaceutical industry and the Brazilian people. They pointed out that Brazil has the second largest pharmaceutical market in the world and that the protection afforded by patent laws is crucial to the growth of the industry.

However, the USG officials and representatives from various companies argued that the Brazilian government has been slow to implement adequate patent laws and that the current system is failing to protect the rights of inventors and companies. They emphasized the need for Brazil to adopt stricter patent protection laws in order to ensure that the country's pharmaceutical industry can thrive.

The meeting ended with a commitment from both sides to continue working together to address the issues raised during the discussions. The USG officials agreed to provide technical assistance and support for Brazil in establishing a more robust patent system, while the Brazilian representatives expressed their willingness to engage in open and constructive dialogue to find solutions to the problems identified during the meeting.

In conclusion, while there are differences in opinion on the issue of patent protection in Brazil, both the USG and Brazilian representatives acknowledged the importance of finding a mutually beneficial solution. The meeting was described as a positive step towards achieving this goal.
8. ON THE QUESTION OF WHAT THE PMA WISH TO ACCOMPLISH THROUGH THE JULI CORRELATON, THE PMA PANELISTS RESPONDED THAT GIVEN THE HISTORY OF THIS ISSUE WITH BRAZIL, IT APPEARED THAT THE ONLY WAY TO "BRING THE GIRL TO THE TABLE" SERIOUSLY WAS TO FILE A JUR CORRELATION. IN REGARD TO THE
CHARGES THAT THE PMA WOULD LIKE TO SEE IN BRAZIL AND FIPR.
PROTECTION FOR PHARMACEUTICALS, THE FOLLOWING SPECIFIC
POSSIBLES WERE MENTIONED: (a) PRODUCT PATENT PROTECTION FOR
NEW ACTIVE INGREDIENTS, (b) PRODUCT BY PROCESS PROTECTION,
(c) REVERSAL OF THE BAN ON PATENT INFRINGEMENT CASES,
(d) NO COMPELLING LICENCISS, (e) LOWER PATENT
VALIDITIES, AND (f) BETTER PATENT ENFORCEMENT. IN
RESPONSE TO A QUESTION, PMA PRESIDENT KOSHER CLEARLY
INDICATED THAT THE PMA WOULD NOT ACCEPT AN INTERIM OR
COMPROMISE SOLUTION TO THE JUR CORRELATION.

9. THE PMA REPRESENTATIVES NOTED THAT A NUMBER OF OTHER
COUNTRIES ALSO HAVE INADEQUATE PATENT PROTECTION FOR
PHARMACEUTICALS, BUT WOULD NOT SPECIFICALLY DISCUSS PLANS
TO FILE OTHER JUR CORRELATIONS. IN RESPONSE TO A RELATED
QUESTION THE PMA SAID THAT IT HAD BEEN IN CONTACT WITH ITS
EUROPEAN COUNTERPART ORGANIZATIONS, WHICH SHARE PMA
CONCERNS AND SUPPORT ITS ACTION AGAINST BRAZIL. THE PMA
WAS NOT AWARE, HOWEVER, WHETHER THE ECU WAS CONSIDERING
TAKE SIMILAR ACTION AGAINST BRAZIL.

10. ATTENDANCE AND INTEREST
THE MEETINGS WERE RELATIVELY WELL ATTENDED. AUDIENCE
LARGELY CONSISTED OF PMA COMPANIES AND OTHERS WITH A PMA
CONNECTION. MEETINGS COINCIDED WITH PMA BOARD MEETINGS AND
USE REPRESENTATIVES. APPROXIMATELY SIX BOLIVIAN MEDIA
REPRESENTATIVES WERE PRESENT. DIPLOMATS FROM BRAZIL,
ARGENTINA, CHILE, AND THE ECU ATTENDED. IN ADDITION, THE
EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRY
ASSOCIATIONS, ALL OF ITS INDIVIDUAL MEMBERS, AND SEVERAL
EUROPEAN NATIONAL INDUSTRY GROUPS SUBMITTED WRITTEN
PRESENTATIONS IN SUPPORT OF THE PMA POSITION.

11. COPIES OF WRITTEN SUBMISSIONS ARE BEING PROMPTED TO
EMBASSY BOLIVIA. COPY OF MEETINGS TRANSCRIPT WILL BE
SENT AS SOON AS IT IS MADE AVAILABLE. WHITEHEAD
BT: #3755